Genexine (095700.KQ) Osake Kurssi

Genexine Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Genexine Inc in the market include other companies operating in the biotechnology and pharmaceutical industries. Some notable competitors include Celltrion Inc, Samsung Biologics, and Hanmi Pharmaceutical Co. These companies also focus on developing and commercializing innovative drugs, therapies, and biologics, which creates a competitive landscape for Genexine Inc in the market.

Genexine Inc is a reputable biotechnology company with a rich history and background. Established in 1999, Genexine has since emerged as a leading player in the field of genetic medicine. The company specializes in developing innovative and effective therapeutics using its cutting-edge platform technologies. Genexine has successfully advanced several clinical candidates that target various diseases, including cancer, infectious diseases, and immune disorders. With a strong focus on research and development, Genexine has gained recognition for its robust pipeline and collaborations with global pharmaceutical companies. As a result, Genexine Inc has established itself as a trusted name in the biotech industry, dedicated to improving patient lives through advanced medical innovation.

Genexine Inc has achieved several significant milestones in its history. These include successful completion of clinical trials for their pipeline products, securing strategic partnerships with renowned pharmaceutical companies, and obtaining regulatory approvals for commercialization. Genexine has also received recognition for its innovative research and development efforts, resulting in numerous patent grants. Additionally, the company has successfully raised capital through public offerings and private placements to support its growth strategy and further advance its portfolio. Through these milestones, Genexine Inc has demonstrated its commitment to advancements in the field of biotechnology and its dedication to improving patient outcomes.

Genexine Inc is primarily present in South Korea, where its headquarters are located.

Genexine Inc represents values of innovation, dedication, and collaboration in the field of biotechnology. The company is committed to developing cutting-edge therapeutics and vaccines to address unmet medical needs. With a focus on research and development, Genexine strives to improve the quality of life for patients worldwide. The company's corporate philosophy emphasizes integrity, transparency, and a patient-centric approach. Genexine Inc aims to create sustainable growth by fostering strong partnerships and expanding its pipeline of innovative drug candidates. With its commitment to scientific advancement and strong corporate values, Genexine Inc is poised to make significant contributions to the biotech industry.

6 analyytikkoa arvioi tällä hetkellä Genexine-osaketta: 0 suosittaa ostoa, 3 pitoa ja 3 myyntiä. Vuodelle 2026 analyytikot odottavat Genexine-yhtiöltä 15,65 Mrd. KRW liikevaihtoa ja −457,90 KRW osakekohtaista tulosta.

Genexine Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Genexine-osake noteerataan hintaan 1,78 EUR (2 670,00 KRW).

Genexine-osake (095700.KQ) on listattuna 1 pörssissä, muun muassa: KOSDAQ (Seoul) (095700.KQ).

Genexine Inc is an emerging biotechnology company based in South Korea. Its goal is to develop and market innovative, highly effective therapies for a variety of diseases. The company has a wide portfolio of products and services focused on three main areas: therapeutics, vaccines, and diagnostics. In the therapeutics field, Genexine focuses on the development of biopharmaceuticals that can be used to treat cancer, autoimmune diseases, and other serious conditions. The company has several potential products in the pipeline, including GX-I7, an immunotherapy for the treatment of metastatic breast cancer, and GX-188E, a DNA vaccine for the treatment of HPV-related cervical cancer. Genexine is also involved in the development of vaccines that can be used to combat infectious diseases such as HPV, influenza, and COVID-19. The company has collaborated with other biotech companies and scientists to develop COVID-19 vaccines that are currently undergoing clinical trials. In addition to therapeutics and vaccines, Genexine also offers diagnostic services. The company has a proprietary technology platform called Polyplex, which can be used for the production of DNA and RNA vaccines, as well as disease diagnosis. By utilizing this technology platform, Genexine can perform accurate and rapid diagnoses of infectious diseases and be able to produce tailored vaccines. Genexine also works closely with other biotechnology companies and academic research institutions. For example, the company has announced a collaboration with BioNTech to develop an mRNA vaccine platform for cancer immunotherapy. The company has also signed a cooperation agreement with the Cleveland Clinic to develop new and innovative therapies for the treatment of cancer and autoimmune diseases. In terms of funding, Genexine enters into strategic partnerships to support the development of its products and services. The company has a business partnership with Chinese company Qilu Pharmaceutical to further develop and market its cancer therapeutics GXNPC. Genexine has also made an agreement with Korean company ToolGen to further develop and market its Polyplex technology platform. Overall, Genexine's business model is focused on developing and bringing to market innovative, highly effective products that can contribute to improving the health and well-being of people worldwide. Through collaboration with strategic partners and a commitment to groundbreaking research and development, Genexine aims to become a leading biotechnology company in the coming years.

odotettu liikevaihto Genexine on 15,65 Mrd. KRW. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Genexine on −20,83 Mrd. KRW. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Genexine:n hinta-voitto-suhde (P/E) on tällä hetkellä −5,83. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Genexine-osakkeen arvostusta.

Genexine:n hinta-myynti-suhde (P/S) on tällä hetkellä 7,76. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Genexine-osakkeen arvostuskennuslukuna.

Genexine:n Eulpool-laatuscore on 2/10.

Genexine:n ISIN on KR7095700001. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Genexine:n ticker on 095700.KQ. Tämä pörssinoteeraus käytetään Genexine-osakkeiden kauppaan pörssissä.